Rapid identification and selection of functional antigen-specific monoclonal antibodies by fcgr-enabled screening on cytosort arrays in the cellraft air system
Ended Project Grant Awarded Last action
- Award ID
- R43AI157022
- Recipient
-
Cell Microsystems Inc. UEI G51EN7YDH7F3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $876,141
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Funding
-
- $584,094.00 Federal
- $292,047.00 Non-federal
- Place of performance
- Durham, NC 27713, USA
Award details come from USAspending.gov.
Description
- Abstract
- The production of antibodies using hybridoma screens and in vitro screening technologies represents one of the most industrialized processes in contemporary life science. Products including research reagents, diagnostic tests and biopharmaceuticals rely on the throughput, efficiency and quality of different antibody screening and manufacturing methods. Despite the large-scale and high-quality requirements of these industries, automation of the process for selecting specific antibodies for manufacturing remains an unmet need. The cellraft technology represents a novel means of imaging, sorting and isolating single cells and clonal colonies. By imaging cells on the proprietary cytosort array on the cellraft air® system, phenotypes can be characterized in detail and over time, prior to isolating cells and colonies for downstream propagation. During this phase i program, we will test and develop novel reporter cell lines, software, and cell-based CO-culture assays that leverage our cellraft air system as an automated antibody screening platform. Briefly, the cellraft technology relies on the cytosort array, which contains thousands of microwells, each featuring a releasable plastic floor where cells are seeded and cultured. Cells are phenotypically monitored on the array with the imaging capabilities of the cellraft air system. Using the air system software, cells can be tracked over time for various phenotypes as well as expansion into clonal colonies. The air system provides a cost-effective, efficient, and robust platform for screening the production, affinity and functionality of monoclonal antibody producing cells (e.g. hybridomas) prior to sorting so only the most promising candidates need to be harvested. During phase i, to demonstrate proof-of-concept, we will optimize a novel hybridoma and jurkat reporter cell line CO-culture on the cytosort array and evaluate a high throughput workflow for assessing antibody production and functionality. Current technologies offering automated solutions to this challenging workflow are incapable of rivaling the cost savings, throughput, and the detailed phenotypic characterization proposed here.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $292,047 | $0 | |
| Original award | $292,047 | $292,047 |
Quick answers
Who received award R43AI157022?
R43AI157022 was awarded to Cell Microsystems Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on January 1, 2021.
How much is award R43AI157022 worth?
$876,141 has been obligated on R43AI157022: $584,094 in federal funding and $292,047 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award